MRNA Moderna Stock Forecast for the Next 12 Months is $165

MRNA Moderna Stock Forecast for the Next 12 Months is $165

Moderna Inc Latest Price

MRNA has 48 drug projects in the pipeline and 35 ongoing clinical trials. Despite being a pharmaceutical company it was ranked 6th on Deloitte’s technology fast 500 growing companies. It was one of those rare jewels that gave out robust earnings during the pandemic.

Latest News

  • MRNA to hold a Webcast – the biotechnology company, is to hold a Piper Sandler 34th Annual Healthcare Conference, today (1/12/22) at 9 am.
  • Improvement in a phase 2/3 trial of mRNA-1273.222 – this Omicron vaccine has completed significantly higher neutralizing antibody titers against the previous booster dose mRNA-1272.
  • Appointment of new general manager – MRNA has hired a Johnson and Johnson employee who has worn various leadership shoes for Medical Devices, Consumer Health, and Pharmaceutical sectors, across four continents  David Jiménez

Latest Earnings

  • For the 3rd quarter, Moderna reported revenue of $3.4 billion, more than a billion dollar decline from the previous quarter which was $4.7 billion.
  • Net income recorded for the 3rd quarter was $1 billion, in Q2 it was $2.1 billion and in Q1 it was reported as $3.6 billion.
  • EBITDA for the latest quarter was $1.2 billion and EPS for the same is $2.53, however, EPS is Q2 was $5.2.
  • The company’s total research and development expenses are $820 million.

Modern Stock Forecast for the Next 12 Months

Average Moderna Stock Forecast for the Next 12 Months$165
Argus$150
Tier1$180
Deutsche Bank$165

Track other Stock Forecasts here

Moderna Stock Forecast: Company Background

Moderna Inc is a pharmaceutical and biotechnology company based in Cambridge, Massachusetts, focusing on RNA therapeutics and primarily mRNA vaccines. Molecule messenger RNA (mRNA) is used by these vaccines to produce an immune response. The company’s commercial product includes the Moderna COVID-19 vaccine. The company has 23 other treatment and vaccine candidates out of which 15 have entered clinical trials. Vaccine candidates include HIV, influenza, a combined single shot for COVID-19 booster, and two cancer vaccines.

The former company’s name was ModeRNA Therapeutics (2010-2018). In 2018, the company rebranded as “Moderna Inc” and further increased its portfolio. In December 2018, Moderna went public with the largest biotech IPO raising $621 million (27 million shares at $23 per share)

Note: Crowdwisdom360 collates Predictions and data from all over the net and has no in-house view on the likely trends in the Stocks or Crypto Coins. Please consult a registered investment advisor to guide you on your financial decisions.

Moderna Stock Forecast for the Next 12 Months is $165
Vineet

Vineet

Vineet Agarwal is a trained technical analyst and avid stock trader. A graduate from a Top Technology Institute, Vineet carries out extensive technical and secondary research for this authored stock forecasts.